Thyroid Cancer Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017

Wednesday, October 25, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Oct. 25, 2017 /PRNewswire/ -- Thyroid Cancer clinical trials report from VPA Research provides comprehensive analysis

and trends in global Thyroid Cancer disease clinical trials. The research work analyzes the evolution of Thyroid Cancer clinical trial trends across countries and regions.Download the full report: report
focuses on drugs and therapies being evaluated for Thyroid Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Thyroid Cancer clinical trials.Major drugs under development in Thyroid Cancer are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.Scope of the Report-- Number of Thyroid Cancer clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas- Trial information by Phase and Subjects recruited- Trial information by status, type, sponsor type- Drugs used for treatment of Thyroid Cancer- Both observational and interventional trials analyzed- Success rates of trials are analyzed- Trends in enrollment over the past ten years identified- Leading sponsors of Thyroid Cancer clinical trials worldwide are listedReasons to Buy-- Track competition and design competitive advantages- Identify right partners to associate with for further research- Evaluate potential opportunities available in further clinical trials of the disease- Formulate business development strategies through success rates of clinical trials- Identify quick markets for recruiting subjects based on trials count by each marketExecutive SummaryThyroid Cancer is the cancer type originating in Thyroid gland. Though specific causes are not determined, the cancer occurs when thyroid cells undergo mutations, making cells to increase rapidly in count and size, forming tumors.Types-Thyroid Cancer is categorized into three main types –Differentiated Thyroid CancerPapillaryFollicularHurthleMedullary Thyroid CancerSporadicFamilialAnaplastic Thyroid CancerStages-Stage I - Tumor less than 2 cmStage II - Tumor between 2 cm and 4 cmStage III - Tumor more than 4 cm, or grown slightly beyond thyroidStage IVa- Tumor expands into nearby neck tissues/ some lymph nodes/ upper chestStage IVb- tumor expands to spine/ blood vesselsStage IVC: Tumor might be spread to distant sites of bodyDrugs in Clinical Trials Development in Thyroid Cancer include-AdalimumabAfatinibAldesleukinAlectinibAlendronate SodiumAlfacalcidolAnlotinibApatinibAtezolizumabAvelumabAzacitidineAZD4547AZD5363BevacizumabBinimetinibBojung-ikgitangBuparlisibCabozantinibCalcium AluminosilicatecarboplatinCediranib MaleateCeritinibCholecystokininCisplatinCobimetinibCrizotinibCrolibulinCyclophosphamideDabrafenibDasatinibDefactinibdexamethasoneDocetaxelDovitinibDoxepin HydrochlorideDoxorubicindurvalumabefatutazoneEntrectinibEtoposideEverolimusFerumoxytolFibrinogen HumanFludarabineFosbretabulinGallium-68-IMP-288gemcitabineGSK2636771IACS-010759IfosfamideIobenguaneIpilimumabLapatinibLarotrectinibLenalidomideLenvatinibLevothyroxinelidocaineLiothyronineLipoic AcidLOXO-195LOXO-292Metforminminodronic acidNab-Paclitaxel(Abraxane)nanocurcuminNeratinibNintedanibNivolumabOctreotide AcetateOfranergene obadenovecOlaparibomeprazoleOsimertiniboxaliplatinePaclitaxelPalbociclibPanobinostatPasireotidepazopanibPembrolizumabPF-04518600PilocarpinePioglitazonePLX8394PonatinibPseudomonas AeruginosaRanitidineRegorafenibRosiglitazoneRovalpituzumab tesirineSacituzumab govitecanSapanisertibSelumetinibSirolimusSorafenibSulfatinibSunitinib MalateTAEST16001TaselisibTc 99m pertechnetatetemsirolimusTetrafluoroborateTF 2Thyrotropin alfaTipifarnibTrametinibtremelimumabUtomilumabValproic AcidVandetanibvemurafenib[18 F]-6-L-fluorodihydroxyphenylalanine111In-CP0418F-Fludeoxyglucose68Ga DOTATATE99Tc-MethylenediphosphonateDownload the full report: About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers  For more information: Sarah Smith Research Advisor at Email:  Tel: +44 208 816 85 48 Website:

View original content:

SOURCE ReportBuyer


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store